Embryo-fetal developmental toxicity study design for pharmaceuticals

✍ Scribed by L. David Wise; Jochen Buschmann; Maureen H. Feuston; J. Edward Fisher; Kok Wah Hew; Alan M. Hoberman; Steven A. Lerman; Yojiro Ooshima; Donald G. Stump

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 136 KB
• Volume: 86
• Category: Article
• ISSN: 1542-9733
• DOI: 10.1002/bdrb.20214

✦ Synopsis

Abstract

Assessment of potential developmental and reproductive toxicity of human pharmaceuticals is currently guided by the International Conference on Harmonization (ICH) S5(R2) document (available at http://www.ich.org). The studies that assess developmental hazard are generally conducted in rodents and rabbits. Based on the authors' collective experience, adequate designs (including range‐finding studies) and the presentation of data for these studies are described in detail. In addition, the suggested initiation and then total duration of these studies in relation to clinical studies that enroll women of childbearing potential are described. Optional parameters that may be included in the studies are discussed, as are study designs that combine assessments of fertility and developmental toxicity. New methods that may replace or enhance current procedures are outlined. The details described herein will assist all laboratories performing these studies, individuals who need to plan for the studies, and regulatory agencies that ultimately review these studies. Birth Defects Res (Part B) 86:418–428, 2009. © 2009 Wiley‐Liss, Inc.